Amarillo, TX – U.S. District Judge Matthew Kacsmaryk in Texas, ruled Friday to suspend approval by the U.S. Food and Drug Administration (FDA) of mifepristone, the first of the two drugs taken to induce a chemical abortion.
Attorneys for the Alliance for Hippocratic Medicine, the plaintiff in the case against the FDA, argue that scientific testing or clinical trials were not performed to establish the drug’s safety and efficacy.
In Judge Kacsmaryk’s 67-page ruling, he did not permanently invalidate the FDA’s approval of the drug. Rather the approval is suspended, and distribution of Mifepristone will be prohibited throughout the U.S. while the case plays out.
The implications of this decision are monumental, as more than half (53%) of all abortions committed in the U.S. currently are by use of mifepristone followed by misoprostol.
As the number of chemical abortions has increased, so have abortion complications. The CDC’s latest data reveals that of approximately 620,327 abortions that took place in 2020, 12,460 mothers experienced some type of complication.
The Charlotte Lozier Institute has reported that chemical abortions have a complication rate four times higher than surgical abortions.
The suspension will take effect in seven days. Until then, the Biden Administration can file an appeal.
“We have waited for this decision and are grateful for the suspension of this incredibly dangerous drug being pushed by our current administration, the media, and the abortion cartel that has been enjoying an easy profit at the expense of mothers and their babies,” said Operation Rescue President Troy Newman.
“Every day this decision stands, the lives of babies are saved and women are protected from extremely painful and potentially life-threatening complications. This is a victory worth celebrating!”
